İstanbul escort bayan sivas escort samsun escort bayan sakarya escort Muğla escort Mersin escort Escort malatya Escort konya Kocaeli Escort Kayseri Escort izmir escort bayan hatay bayan escort antep Escort bayan eskişehir escort bayan erzurum escort bayan elazığ escort diyarbakır escort escort bayan Çanakkale Bursa Escort bayan Balıkesir escort aydın Escort Antalya Escort ankara bayan escort Adana Escort bayan

Esteve Will Sell Its First Own Product In The US

Date:

Esteve will sell its first own product in the US. The firm receives FDA approval to develop Seglentis, a co-crystal of celecoxib and tramadol against acute processes.

The US health authority (FDA) has approved a drug from the Catalan pharmaceutical company Esteve to treat acute pain in adults, a drug that is the first product of this company’s own research to be marketed in the US .

Seglentis (celecoxib and tramadol hydrochloride) is a drug developed by Esteve’s R&D team, the first of its kind, composed of a cocrystalline form of celecoxib (anti-inflammatory) and tramadol (analgesic) for the treatment of acute pain in Adults. It offers a new acute pain treatment option aligned with multimodal analgesia, currently considered the standard of care for pain control.

The scientific and medical director of Esteve, Carlos Plata-Salamán, has commented that this innovation “is the result of applying a crystallization technology to improve the physicochemical properties and the pharmacokinetic characteristics of its active pharmaceutical ingredients”.

It is an analgesic that Esteve will market in the US through Kowa Pharmaceuticals America and that is designed for the treatment of acute pain following a multimodal treatment approach aimed at four complementary pain relief mechanisms.

Esteve assures that the drug represents a new option for the treatment of acute pain aligned with multimodal analgesia, currently considered the standard of care for pain control. Esteve’s CEO, Staffan Schüberg, said that the company is “very proud” of this achievement, as “it is recognition of our daily efforts to meet the needs of patients and address the current challenges of treating acute pain. “, has added.

Esteve is a global pharmaceutical company based in Barcelona. It has an important presence in Europe through subsidiary subsidiaries and its own production facilities dedicated to the development and manufacture of active pharmaceutical ingredients in Spain, Mexico and China, and a pharmaceutical plant in Germany.

Share post:

Popular

More like this
Related

The Role of Unlisted Shares in Wealth Management Portfolios

Contributing is not bound to the recognizable domain of...

The Founder of Sleeping Dog Properties, Chris Rapczynski is Committed to Building Better Homes and a Better World

Climate change, shortage of water, and a rapidly deteriorating...

Rising inflation proves cost of living crisis is far from over, warns the Women’s Budget Group

The unexpected uptick in inflation to 4% from 3.9%,...

Türkiye’s leading home and lifestyle brand Karaca expands its presence in the UK

Karaca brand, a brand that enjoys a well-established  50-year...